N-(4-hydroxybenzyl)formamide | 86386-69-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(4-hydroxybenzyl)formamide
• 英文别名: N-[(4-hydroxyphenyl)methyl]formamide；4-hydroxybenzylamine；N-(4-Hydroxy-benzyl)-formamid
• CAS: 86386-69-8
• 化学式: C₈H₉NO₂
• 分子量: 151.165
• InChiKey: JCDWXESTXVUQNR-UHFFFAOYSA-N

物化性质

• 沸点：
  418.2±28.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-hydroxybenzyl)formamide 在 三光气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 0.67h， 生成 N-(tert-butyl)-N-(2-((4-hydroxybenzyl)amino)-2-oxo-1-(p-tolyl)ethyl)pentanamide
  参考文献：
  名称：

  Efficient Isocyanide-less Isocyanide-Based Multicomponent Reactions

  摘要：

  Isocyanides are the "Jekyll and Hyde" of organic chemistry allowing for extremely interesting transformations that are not only extremely odorous but also noxious. Therefore, an isocyanide-less isocyanide-based multicomponent reaction (IMCR) has been developed, and this protocol is expected to replace many of the old procedures in the future not only in IMCR but in other areas of organic chemistry as well.

  DOI：

  10.1021/acs.orglett.5b00759
• 作为产物：
  描述：

  4-羟基苯甲腈 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 10.0h， 生成 N-(4-hydroxybenzyl)formamide
  参考文献：
  名称：

  Design of inhibitors from the three-dimensional structure of alcohol dehydrogenase. Chemical synthesis and enzymic properties

  摘要：

  DOI：

  10.1021/ja00323a048

文献信息

• First report on bio-catalytic N-formylation of amines using ethyl formate
  作者：Rupesh E. Patre、Sanjib Mal、Pankaj R. Nilkanth、Sujit K. Ghorai、Sudhindra H. Deshpande、Myriem El Qacemi、Tomas Smejkal、Sitaram Pal、Bhanu N. Manjunath

  DOI：10.1039/c6cc07679c

  日期：——

  A Bio-catalyzed N-formylation reaction of different amines has been developed using ethyl formate as formylating agent. This protocol provides a facile and convenient strategy featuring mild reaction condition, high efficacy,...

  使用甲酸乙酯作为甲酰化剂，已经开发了不同胺的生物催化的N-甲酰化反应。该协议提供了一种轻而易举的策略，具有反应条件温和，疗效高，...
• Bicyclic Heterocycles from Levulinic Acid through a Fast and Operationally Simple Diversity-Oriented Multicomponent Approach
  作者：Chiara Lambruschini、Andrea Basso、Lisa Moni、Alessandro Pinna、Renata Riva、Luca Banfi

  DOI：10.1002/ejoc.201801129

  日期：2018.10.24

  Operationally simple, 2‐step conversion of levulinic acid into bicyclic drug‐like heterocyclic systems.

  乙酰丙酸操作简单，两步转化为双环类药物杂环系统。
• Estrogen receptor modulators
  申请人：CHIRON CORPORATION

  公开号：US20040077701A1

  公开（公告）日：2004-04-22

  Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

  本文描述了调节雌激素受体的吡唑化合物，以及用于治疗或预防雌激素受体介导的疾病的方法和组合物。所述化合物已被发现具有意外和惊人的调节雌激素受体活性的活性。因此，本发明的化合物在预防或治疗雌激素受体介导的疾病，如骨质疏松症、乳腺和子宫内膜癌、动脉硬化和阿尔茨海默病中具有实用性。
• Method of determining potential allosterically-binding matrix metalloproteinase inhibitors
  申请人：Andrianjara Charles

  公开号：US20050004126A1

  公开（公告）日：2005-01-06

  Compounds are provided that bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond respectively with Thr245, Thr 247 and Met 253, the first hydrophobic group locates within the S1′ channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compounds specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

  提供了一种与MMP-13催化域发生变构作用的化合物，其中包括一个疏水基团、第一和第二氢键受体以及至少一个第三氢键受体和第二个疏水基团，最好是两者都有。上述特征的笛卡尔坐标在说明书中有定义。当配体与MMP-13结合时，第一、第二和第三（存在时）氢键受体分别与Thr245、Thr 247和Met 253结合，第一疏水基团位于MMP-13的S1'通道内，第二疏水基团（存在时）相对于溶剂较为开放。这些化合物特异性地抑制了基质金属蛋白酶-13酶，因此可用于治疗由组织分解引起的疾病，如心脏病、多发性硬化症、关节炎、动脉粥样硬化和骨质疏松症。
• ESTROGEN RECEPTOR MODULATORS
  申请人：Chiron Corporation

  公开号：US20040034081A9

  公开（公告）日：2004-02-19

  Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

  本文描述了调节雌激素受体的吡唑类化合物，以及用于治疗或预防雌激素受体介导的疾病的方法和组合物。所述化合物已被发现具有意外和惊人的调节雌激素受体活性的活性。因此，本发明的化合物在预防或治疗雌激素受体介导的疾病，如骨质疏松症、乳腺和子宫内膜癌、动脉粥样硬化和阿尔茨海默病中具有实用价值。